Transforming Pain Management: Suzetrigine, a Novel Non-Opioid Analgesic
Abstract
Suzetrigine is a novel non-opioid analgesic that selectively inhibits the Nav1.8 sodium channel, which plays a key role in peripheral pain signaling. By blocking action potential propagation in nociceptors, it effectively reduces pain without affecting the central nervous system, thus avoiding the risks associated with opioids, such as addiction and respiratory depression. In two phase 2 clinical trials, suzetrigine demonstrated superior pain control compared to placebo and showed comparable effectiveness to hydrocodone/acetaminophen for treating moderate to severe acute pain after abdominoplasty and bunionectomy with an acceptable safety profile. Current findings support suzetrigine's potential role as a safer alternative to opioids in managing moderate to severe pain.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.